Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Specimen Handling 662pembrolizumab 612Magnetic Resonance Spectroscopy 565Carboplatin 451Cisplatin 400Cyclophosphamide 399Biopsy 385Nivolumab 329Paclitaxel 324Gemcitabine 317Radiotherapy 302Bevacizumab 250Dexamethasone 223fludarabine 217Docetaxel 203durvalumab 196Oxaliplatin 189venetoclax 188atezolizumab 188Fluorouracil 178Rituximab 177Pemetrexed 174Capecitabine 172Radiation 171Doxorubicin 168Radiosurgery 161Ipilimumab 149Etoposide 142Leucovorin 141Lenalidomide 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ibritumomab tiuxetan × 90 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡